1. Medtech Insight
  2. >>Device Area

AAOS Roundup: Robotic Ortho Surgery Continues To Gain Traction, Led By Stryker's MAKO

 
• By Marion Webb

Stryker is enjoying strong demand for its MAKO robotic surgery platform with plans to increase system placements and procedure volumes while working on a next-gen system that would enhance ease-of-use for surgeons and improve accuracy. The company also has plans to expand into other areas of focus, according to analyst reports from this year's AAOS annual meeting in New Orleans. Meanwhile, Smith & Nephew and Zimmer Biomet are trying to set themselves apart with their robotic technologies.

Human joints, knee and elbow joint, ankle joint and wrist. Medical orthopedic vector set. Anatomy human orthopedic illustration of leg and hand

The robotic movement continues to gain traction with orthopedic surgeons. To further cement their bond with surgeons, the major developers of robotic systems for large joints led by Stryker Corp., as well as Smith & Nephew PLC and Zimmer Biomet Holdings Inc., are presenting their latest news on the sales and marketing front, next-gen applications and clinical study findings at this year's Annual Meeting of the American Academy of Orthopedic Surgeons (AAOS 2018), held March 3-10 in New Orleans. Also see "Latest Mako Tech Fleshes Out Stryker's Robotic Joint Replacement Line But Cost Critics Still There" - Medtech Insight, 20 March, 2017.

After Stryker's big fanfare introduction of the MAKO total knee replacement system last March at AAOS 2017 in San Diego, the company finished 2017 with strong US knee growth, up...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Orthopedics

More from Device Area

FDLI: Clinical Labs Face Uncertainty After Texas Court’s LDT Ruling

 
• By Elizabeth Orr

A Texas court's decision against US FDA regulation of lab-developed tests (LDTs) has introduced new uncertainties for clinical labs. Industry stakeholders are now worried about potential future regulations while also managing existing compliance requirements. Recent conference discussions underscored the complexities of FDA oversight.

Data Finds Capillary Blood Is A Reliable Alternative To Venous Blood For Routine Testing

 
• By Natasha Barrow

A study from Babson Diagnostics published in the peer-reviewed Journal of Applied Laboratory Medicine showed that capillary blood sample volume issues can overcome historical challenges, such as poor quality, through a technique called assay miniaturization.

First Alzheimer’s Disease Diagnostic Blood Test Cleared By FDA

 
• By Natasha Barrow

Fujirebio Diagnostics' Alzheimer's disease test, Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, has been cleared by the US FDA.